SG11201700066TA - Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same - Google Patents
Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing sameInfo
- Publication number
- SG11201700066TA SG11201700066TA SG11201700066TA SG11201700066TA SG11201700066TA SG 11201700066T A SG11201700066T A SG 11201700066TA SG 11201700066T A SG11201700066T A SG 11201700066TA SG 11201700066T A SG11201700066T A SG 11201700066TA SG 11201700066T A SG11201700066T A SG 11201700066TA
- Authority
- SG
- Singapore
- Prior art keywords
- oxazolidin
- triazin
- thiophene
- dihydro
- oxo
- Prior art date
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2014/006555 WO2016010178A1 (en) | 2014-07-18 | 2014-07-18 | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201700066TA true SG11201700066TA (en) | 2017-02-27 |
Family
ID=55078662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700066TA SG11201700066TA (en) | 2014-07-18 | 2014-07-18 | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same |
Country Status (16)
Country | Link |
---|---|
US (1) | US9988372B2 (en) |
EP (1) | EP3170819B1 (en) |
JP (1) | JP6450840B2 (en) |
KR (1) | KR102100357B1 (en) |
CN (2) | CN106661011B (en) |
AU (1) | AU2014400894B2 (en) |
BR (1) | BR112017000351B1 (en) |
CA (1) | CA2955397C (en) |
IL (2) | IL297649A (en) |
MX (1) | MX2017000409A (en) |
MY (1) | MY190477A (en) |
PH (1) | PH12017500093A1 (en) |
RU (1) | RU2663617C1 (en) |
SG (1) | SG11201700066TA (en) |
UA (1) | UA116182C2 (en) |
WO (1) | WO2016010178A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3789388B1 (en) * | 2018-05-02 | 2024-01-24 | Tianjin Hemay Pharmaceutical Co., Ltd. | Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100898361B1 (en) * | 2008-07-03 | 2009-05-20 | 주식회사 레고켐 바이오사이언스 | Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof |
KR101037052B1 (en) * | 2009-07-08 | 2011-05-26 | 주식회사 레고켐 바이오사이언스 | Method for preparing 5-chloro-N-5S-2-oxo-3-4-5,6-dihydro-1,2,4-triazin-14H-ylphenyl-1,3-oxazolidin-5-ylmethylthiophen-2-carboxamide derivatives, and their intermediates |
-
2014
- 2014-07-18 CN CN201480080661.8A patent/CN106661011B/en active Active
- 2014-07-18 CN CN201910687566.9A patent/CN110407827B/en active Active
- 2014-07-18 UA UAA201701494A patent/UA116182C2/en unknown
- 2014-07-18 IL IL297649A patent/IL297649A/en unknown
- 2014-07-18 KR KR1020167035812A patent/KR102100357B1/en active IP Right Grant
- 2014-07-18 AU AU2014400894A patent/AU2014400894B2/en active Active
- 2014-07-18 CA CA2955397A patent/CA2955397C/en active Active
- 2014-07-18 MY MYPI2016704816A patent/MY190477A/en unknown
- 2014-07-18 SG SG11201700066TA patent/SG11201700066TA/en unknown
- 2014-07-18 MX MX2017000409A patent/MX2017000409A/en active IP Right Grant
- 2014-07-18 RU RU2017105147A patent/RU2663617C1/en active
- 2014-07-18 BR BR112017000351-1A patent/BR112017000351B1/en active IP Right Grant
- 2014-07-18 JP JP2017523744A patent/JP6450840B2/en active Active
- 2014-07-18 WO PCT/KR2014/006555 patent/WO2016010178A1/en active Application Filing
- 2014-07-18 EP EP14897871.1A patent/EP3170819B1/en active Active
- 2014-07-18 US US15/325,521 patent/US9988372B2/en active Active
-
2017
- 2017-01-13 PH PH12017500093A patent/PH12017500093A1/en unknown
- 2017-01-17 IL IL250168A patent/IL250168A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2017000409A (en) | 2017-05-01 |
JP2017521500A (en) | 2017-08-03 |
PH12017500093A1 (en) | 2017-05-22 |
WO2016010178A1 (en) | 2016-01-21 |
KR20170023003A (en) | 2017-03-02 |
US9988372B2 (en) | 2018-06-05 |
IL250168A0 (en) | 2017-03-30 |
CA2955397A1 (en) | 2016-01-21 |
AU2014400894B2 (en) | 2018-04-19 |
EP3170819A1 (en) | 2017-05-24 |
RU2663617C1 (en) | 2018-08-07 |
JP6450840B2 (en) | 2019-01-09 |
BR112017000351B1 (en) | 2022-10-25 |
CN110407827B (en) | 2023-05-23 |
MY190477A (en) | 2022-04-22 |
EP3170819B1 (en) | 2019-07-10 |
CA2955397C (en) | 2019-01-08 |
CN106661011B (en) | 2020-01-10 |
AU2014400894A1 (en) | 2017-02-02 |
KR102100357B1 (en) | 2020-04-13 |
NZ727829A (en) | 2021-01-29 |
CN110407827A (en) | 2019-11-05 |
US20170152251A1 (en) | 2017-06-01 |
EP3170819A4 (en) | 2018-05-16 |
BR112017000351A2 (en) | 2017-11-07 |
UA116182C2 (en) | 2018-02-12 |
IL297649A (en) | 2022-12-01 |
CN106661011A (en) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL236455A0 (en) | Pharmaceutical administration forms comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | |
IL210483A0 (en) | Pharmaceutical compositions comprising 5-chlooro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid | |
MY176244A (en) | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | |
PH12016500988B1 (en) | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists | |
HK1251557A1 (en) | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol | |
EP3262039A4 (en) | Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof | |
IL252744A0 (en) | Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof | |
IL250168A0 (en) | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same | |
WO2014141067A3 (en) | Process for the preparation of oxazolidinone derivatives | |
IL249248A0 (en) | Anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole | |
IN2012MU03359A (en) | ||
MX2016013875A (en) | Active ingredient (i) containing composition and method for preparing same. | |
WO2012080184A3 (en) | Liquid pharmaceutical compositions which can be administered orally and contain 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide | |
IL263299A (en) | Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent | |
JO3292B1 (en) | Novel salt of 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, preparation thereof and formulations containing same | |
EP2451803A4 (en) | Method for preparing 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophen-2-carboxamide derivative and intermediate used therein | |
LT3468957T (en) | Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent | |
TH1601000138A (en) | A new type of salt 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3 -dihydro-1H-indole-5-yl)methyl]-1,3-thiazolidine-2,4-dione Its preparation and formulations containing it | |
CU20080051A7 (en) | NEW POLYMORPHIC FORM AND THE AMORPHY FORM OF 5-CHLORINE-N - ({(5S) -2-OXO-3- [4- (3-OXO-4-MORFOLINIL) -FENIL] -1,3-OXAZOLIDIN-5- IL} -METIL) -2-THIOPHENOCARBOXAMIDE |